192 related articles for article (PubMed ID: 34737211)
1. Loss of FBXW7 Correlates with Increased IDH1 Expression in Glioma and Enhances IDH1-Mutant Cancer Cell Sensitivity to Radiation.
Yang Z; Hu N; Wang W; Hu W; Zhou S; Shi J; Li M; Jing Z; Chen C; Zhang X; Yang R; Fu X; Wang X
Cancer Res; 2022 Feb; 82(3):497-509. PubMed ID: 34737211
[TBL] [Abstract][Full Text] [Related]
2. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
[TBL] [Abstract][Full Text] [Related]
3. Cyclin F-Dependent Degradation of RBPJ Inhibits IDH1
Deshmukh RS; Sharma S; Das S
Cancer Res; 2018 Nov; 78(22):6386-6398. PubMed ID: 30254149
[TBL] [Abstract][Full Text] [Related]
4. The WD40 domain of FBXW7 is a poly(ADP-ribose)-binding domain that mediates the early DNA damage response.
Zhang Q; Mady ASA; Ma Y; Ryan C; Lawrence TS; Nikolovska-Coleska Z; Sun Y; Morgan MA
Nucleic Acids Res; 2019 May; 47(8):4039-4053. PubMed ID: 30722038
[TBL] [Abstract][Full Text] [Related]
5. An in vivo patient-derived model of endogenous IDH1-mutant glioma.
Luchman HA; Stechishin OD; Dang NH; Blough MD; Chesnelong C; Kelly JJ; Nguyen SA; Chan JA; Weljie AM; Cairncross JG; Weiss S
Neuro Oncol; 2012 Feb; 14(2):184-91. PubMed ID: 22166263
[TBL] [Abstract][Full Text] [Related]
6. Lack of evidence for substrate channeling or flux between wildtype and mutant isocitrate dehydrogenase to produce the oncometabolite 2-hydroxyglutarate.
Dexter JP; Ward PS; Dasgupta T; Hosios AM; Gunawardena J; Vander Heiden MG
J Biol Chem; 2018 Dec; 293(52):20051-20061. PubMed ID: 30381394
[TBL] [Abstract][Full Text] [Related]
7. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response.
Núñez FJ; Mendez FM; Kadiyala P; Alghamri MS; Savelieff MG; Garcia-Fabiani MB; Haase S; Koschmann C; Calinescu AA; Kamran N; Saxena M; Patel R; Carney S; Guo MZ; Edwards M; Ljungman M; Qin T; Sartor MA; Tagett R; Venneti S; Brosnan-Cashman J; Meeker A; Gorbunova V; Zhao L; Kremer DM; Zhang L; Lyssiotis CA; Jones L; Herting CJ; Ross JL; Hambardzumyan D; Hervey-Jumper S; Figueroa ME; Lowenstein PR; Castro MG
Sci Transl Med; 2019 Feb; 11(479):. PubMed ID: 30760578
[TBL] [Abstract][Full Text] [Related]
8. Vulnerability of IDH1-Mutant Cancers to Histone Deacetylase Inhibition via Orthogonal Suppression of DNA Repair.
Dow J; Krysztofiak A; Liu Y; Colon-Rios DA; Rogers FA; Glazer PM
Mol Cancer Res; 2021 Dec; 19(12):2057-2067. PubMed ID: 34535560
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
Li S; Chou AP; Chen W; Chen R; Deng Y; Phillips HS; Selfridge J; Zurayk M; Lou JJ; Everson RG; Wu KC; Faull KF; Cloughesy T; Liau LM; Lai A
Neuro Oncol; 2013 Jan; 15(1):57-68. PubMed ID: 23115158
[TBL] [Abstract][Full Text] [Related]
10. Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1
Waitkus MS; Pirozzi CJ; Moure CJ; Diplas BH; Hansen LJ; Carpenter AB; Yang R; Wang Z; Ingram BO; Karoly ED; Mohney RP; Spasojevic I; McLendon RE; Friedman HS; He Y; Bigner DD; Yan H
Cancer Res; 2018 Jan; 78(1):36-50. PubMed ID: 29097607
[TBL] [Abstract][Full Text] [Related]
11. Isocitrate dehydrogenase 1 mutation enhances 24(S)-hydroxycholesterol production and alters cholesterol homeostasis in glioma.
Yang R; Zhao Y; Gu Y; Yang Y; Gao X; Yuan Y; Xiao L; Zhang J; Sun C; Yang H; Qin J; Li J; Zhang F; Zhang L; Ye J
Oncogene; 2020 Oct; 39(40):6340-6353. PubMed ID: 32855525
[TBL] [Abstract][Full Text] [Related]
12. Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma.
Mukherjee J; Johannessen TC; Ohba S; Chow TT; Jones L; Pandita A; Pieper RO
Cancer Res; 2018 Jun; 78(11):2966-2977. PubMed ID: 29545335
[TBL] [Abstract][Full Text] [Related]
13. Monoallelic IDH1 R132H Mutation Mediates Glioma Cell Response to Anticancer Therapies via Induction of Senescence.
Zhan D; Ma D; Wei S; Lal B; Fu Y; Eberhart C; Laterra J; Ying M; Li Y; Meeker A; Lopez-Bertoni H; Xia S
Mol Cancer Res; 2021 Nov; 19(11):1878-1888. PubMed ID: 34348994
[TBL] [Abstract][Full Text] [Related]
14. IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced.
Zhu H; Zhang Y; Chen J; Qiu J; Huang K; Wu M; Xia C
PLoS One; 2017; 12(1):e0169038. PubMed ID: 28052098
[TBL] [Abstract][Full Text] [Related]
15. FBXW7 Confers Radiation Survival by Targeting p53 for Degradation.
Cui D; Xiong X; Shu J; Dai X; Sun Y; Zhao Y
Cell Rep; 2020 Jan; 30(2):497-509.e4. PubMed ID: 31940492
[TBL] [Abstract][Full Text] [Related]
16. FBXW7 mediates high glucose‑induced SREBP‑1 expression in renal tubular cells of diabetic nephropathy under PI3K/Akt pathway regulation.
Li L; Yang J; Li F; Gao F; Zhu L; Hao J
Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 33537812
[TBL] [Abstract][Full Text] [Related]
17. Fbxw7 regulates lipid metabolism and cell fate decisions in the mouse liver.
Onoyama I; Suzuki A; Matsumoto A; Tomita K; Katagiri H; Oike Y; Nakayama K; Nakayama KI
J Clin Invest; 2011 Jan; 121(1):342-54. PubMed ID: 21123947
[TBL] [Abstract][Full Text] [Related]
18. Loss of Fbxw7 triggers mammary tumorigenesis associated with E2F/c-Myc activation and Trp53 mutation.
Meyer AE; Furumo Q; Stelloh C; Minella AC; Rao S
Neoplasia; 2020 Nov; 22(11):644-658. PubMed ID: 33070870
[TBL] [Abstract][Full Text] [Related]
19. In vitro effects of FBXW7 mutation in serous endometrial cancer: Increased levels of potentially druggable proteins and sensitivity to SI-2 and dinaciclib.
Urick ME; Bell DW
Mol Carcinog; 2018 Nov; 57(11):1445-1457. PubMed ID: 29963728
[TBL] [Abstract][Full Text] [Related]
20. FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation.
Babaei-Jadidi R; Li N; Saadeddin A; Spencer-Dene B; Jandke A; Muhammad B; Ibrahim EE; Muraleedharan R; Abuzinadah M; Davis H; Lewis A; Watson S; Behrens A; Tomlinson I; Nateri AS
J Exp Med; 2011 Feb; 208(2):295-312. PubMed ID: 21282377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
